Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis
Open accessThe DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Myofibroblasts produce the fibrous scar in hepatic fibrosis. In the carbon tetrachloride (CCl(4)) model of liver fibrosis, quiescent hepatic stellate cells (HSC) are activated to become myofibroblasts. When the underlying etiological agent is removed, clinical and experimental fibrosis undergoes a remarkable regression with complete disappearance of these myofibroblasts. Although some myofibroblasts apoptose, it is unknown whether other myofibroblasts may revert to an inactive phenotype during regression of fibrosis. We elucidated the fate of HSCs/myofibroblasts during recovery from CCl(4)- and alcohol-induced liver fibrosis using Cre-LoxP-based genetic labeling of myofibroblasts. Here we demonstrate that half of the myofibroblasts escape apoptosis during regression of liver fibrosis, down-regulate fibrogenic genes, and acquire a phenotype similar to, but distinct from, quiescent HSCs in their ability to more rapidly reactivate into myofibroblasts in response to fibrogenic stimuli and strongly contribute to liver fibrosis. Inactivation of HSCs was associated with up-regulation of the anti-apoptotic genes Hspa1a/b, which participate in the survival of HSCs in culture and in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conversely, restored RSPO3 expression during HSC deactivation52,53 or by therapeutic interventions might help to regain hepatocyte functions.”
From Hepatic stellate cells control liver zonation, size and functions via R-spondin 3 (2025) · cites this paper as [52]
In the citing paper
“Animal models reinforce the capacity of the injured liver to regress fibrosis and provide important platform for dissecting underlying mechanisms, although it should be noted that fibrosis in mice regresses incredibly rapidly, which may be in part attributed to the short duration of models (weeks to months in mice vs. years to decades in humans) and initiation of fibrosis at relatively young age (”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [262]
In the citing paper
“Fibroblast activation also involves increased activity of key glycolytic enzymes, such as hexokinase 2 and lactate dehydrogenase (LDH)47, which in turn increase cell proliferation47 and collagen synthesis48.”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [47]
In the citing paper
“During enhanced glycolysis, increased amounts of pyruvate are converted to acetyl-CoA in the mitochondrial matrix47 before entering the citric acid cycle. This yields intermediate metabolites, such as succinate, which promote fibrosis49.”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [47]
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Self-citationSenescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
TLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942
Self-citationBataller, R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524282c1 · Cited by 1,472
Iredale, J. P., Benyon, R. C., Pickering, J., McCullen, M., Northrop, M., Pawley, S., Hovell, C., & Arthur, M. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1018 · Cited by 1,075 · cited 8×
“Myofibroblasts are aSMA collagen type I cells that are absent from the normal uninjured liver, rapidly emerge infibrotic liver to produce thefibrous scar, and completely disappear with regression of liver fibrosis (1, 2).”
BackgroundInfluentialThe role of matrix stiffness in regulating cell behavior†
Wells, R. G. (2008) · Hepatology · doi:10.1002/hep.22193 · Cited by 1,059
Hepatic lipocytes: the principal collagen-producing cells of normal rat liver.
Friedman, S. L., Roll, F. J., Boyles, J., & Bissell, D. M. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.24.8681 · Cited by 859
Lee, K. S., Buck, M., Houglum, K., & Chojkier, M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118304 · Cited by 539
Ito Cells Are Liver-Resident Antigen-Presenting Cells for Activating T Cell Responses
Winau, F., Hegasy, G., Weiskirchen, R., Weber, S., Cassan, C., Sieling, P. A., Modlin, R. L., Liblau, R. S., Gressner, A. M., & Kaufmann, S. H. E. (2007) · Immunity · doi:10.1016/j.immuni.2006.11.011 · Cited by 410
Lee, C. G., Cho, S. J., Kang, M. J., Chapoval, S. P., Lee, P. J., Noble, P. W., Yehualaeshet, T., Lu, B., Flavell, R. A., Milbrandt, J., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040104 · Cited by 369
Cited by
Items 201–300 of 889
Review article: the prevention and reversal of hepatic fibrosis in autoimmune hepatitis
Czaja, A. J. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12592 · Cited by 92
Zeybel, M., Luli, S., Sabater, L., Hardy, T., Oakley, F., Leslie, J., Page, A., Moran Salvador, E., Sharkey, V., Tsukamoto, H., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.004 · Cited by 84
Self-citationDeregulated neddylation in liver fibrosis
Zubiete‐Franco, I., Fernández‐Tussy, P., Barbier‐Torres, L., Simón, J., Fernández‐Ramos, D., Lopitz‐Otsoa, F., Juan, V. G., de Davalillo, S. L., Duce, A. M., Iruzubieta, P., et al. (2016) · Hepatology · doi:10.1002/hep.28933 · Cited by 90
Hepatic Stellate Cells and Liver Fibrosis
Puche, J. E., Saiman, Y., & Friedman, S. L. (2013) · Comprehensive Physiology · doi:10.1002/j.2040-4603.2013.tb00529.x · Cited by 89
Zhou, C., York, S. R., Chen, J. Y., Pondick, J. V., Motola, D. L., Chung, R. T., & Mullen, A. C. (2016) · Genome Medicine · doi:10.1186/s13073-016-0285-0 · Cited by 74
Genetic tools for identifying and manipulating fibroblasts in the mouse
Swonger, J. M., Liu, J. S., Ivey, M. J., & Tallquist, M. D. (2016) · Differentiation · doi:10.1016/j.diff.2016.05.009 · Cited by 84
Kuwabara, J. T., & Tallquist, M. D. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.308199 · Cited by 88
Identification of a myofibroblast-specific expression signature in skin wounds
Bergmeier, V., Etich, J., Pitzler, L., Frie, C., Koch, M., Fischer, M., Rappl, G., Abken, H., Tomasek, J. J., & Brachvogel, B. (2018) · Matrix Biology · doi:10.1016/j.matbio.2017.07.005 · Cited by 87
Adiponectin Agonist ADP355 Attenuates CCl4-Induced Liver Fibrosis in Mice
Kumar, P., Smith, T., Rahman, K., Thorn, N. E., & Anania, F. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110405 · Cited by 82
Mesenchymal stromal cells and liver fibrosis: a complicated relationship
Haldar, D., Henderson, N. C., Hirschfield, G., & Newsome, P. N. (2016) · The FASEB Journal · doi:10.1096/fj.201600433r · Cited by 80
Nakano, Y., Kamiya, A., Sumiyoshi, H., Tsuruya, K., Kagawa, T., & Inagaki, Y. (2020) · Hepatology · doi:10.1002/hep.30965 · Cited by 86
Targeting Nestin+ hepatic stellate cells ameliorates liver fibrosis by facilitating TβRI degradation
Chen, H., Cai, J., Wang, J., Qiu, Y., Jiang, C., Wang, Y., Wang, Y., Yi, C., Lv, G., Pan, L., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.016 · Cited by 86
Self-citationRegulation of Hepatic Stellate Cell Phenotypes in Metabolic Dysfunction–Associated Steatohepatitis
Kisseleva, T., Ganguly, S., Murad, R., Wang, A., & Brenner, D. A. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.03.010 · Cited by 86
Self-citationHepatocytes in liver injury: Victim, bystander, or accomplice in progressive fibrosis?
Tu, T., Calabro, S. R., Lee, A., Maczurek, A. E., Budzinska, M. A., Warner, F. J., McLennan, S. V., & Shackel, N. A. (2015) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13065 · Cited by 71
de Mesquita, F. C., Guixé-Muntet, S., Fernández-Iglesias, A., Maeso-Díaz, R., Vila, S., Hide, D., Ortega-Ribera, M., Rosa, J. L., García-Pagán, J. C., Bosch, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-02866-y · Cited by 74
Epigenetic regulation of wound healing and fibrosis
Mann, J., & Mann, D. A. (2012) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32835b13e1 · Cited by 83
Hepatic stellate cells in the injured liver: Perspectives beyond hepatic fibrosis
Ezhilarasan, D. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30582 · Cited by 82
Bollong, M. J., Yang, B., Vergani, N., Beyer, B. A., Chin, E. N., Zambaldo, C., Wang, D., Chatterjee, A. K., Lairson, L. L., & Schultz, P. G. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1702750114 · Cited by 82
Antifibrotic Therapies in the Liver
Schuppan, D., & Mehal, W. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1550055 · Cited by 75
Hepatic Fibrosis: Emerging Therapies
Friedman, S. L. (2015) · Digestive Diseases · doi:10.1159/000374098 · Cited by 68
Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease
Wiering, L., Subramanian, P., & Hammerich, L. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.02.010 · Cited by 80
Review article: the reversibility of cirrhosis
Sohrabpour, A. A., Mohamadnejad, M., & Malekzadeh, R. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12044 · Cited by 80
Molecular Mechanism and Treatment of Viral Hepatitis-Related Liver Fibrosis
Su, T., Kao, J., & Liu, C. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150610578 · Cited by 80
It has to be the αv: myofibroblast integrins activate latent TGF-β1
Hinz, B. (2013) · Nature Medicine · doi:10.1038/nm.3421 · Cited by 80
Torok, N. J., Dranoff, J. A., Schuppan, D., & Friedman, S. L. (2015) · Hepatology · doi:10.1002/hep.27720 · Cited by 68
Crosstalk between hepatic stellate cells and surrounding cells in hepatic fibrosis
Yang, F., Li, H., Li, Y., Hao, Y., Wang, C., Jia, P. P., Chen, X., Ma, S., & Xiao, Z. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108051 · Cited by 78
Metabolic Reprogramming of Liver Fibrosis
Delgado, M. E., Cárdenas, B. I., Farran, N., & Fernandez, M. (2021) · Cells · doi:10.3390/cells10123604 · Cited by 71
Reelin through the years: From brain development to inflammation
Alexander, A., Herz, J., & Calvier, L. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112669 · Cited by 79
Regulators of cardiac fibroblast cell state
Bretherton, R. C., Bugg, D., Olszewski, E., & Davis, J. (2020) · Matrix Biology · doi:10.1016/j.matbio.2020.04.002 · Cited by 77
Emerging therapeutic targets for the treatment of hepatic fibrosis
Fagone, P., Mangano, K., Pesce, A., Portale, T. R., Puleo, S., & Nicoletti, F. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.10.015 · Cited by 77
Novel insights into pericyte–myofibroblast transition and therapeutic targets in renal fibrosis
Chang, F., Chou, Y., Chen, Y., & Lin, S. (2012) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2012.09.008 · Cited by 77
The Role of S1P and the Related Signaling Pathway in the Development of Tissue Fibrosis
Wang, E., He, X., & Zeng, M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01504 · Cited by 77
Epigenetic Mechanisms in Hepatic Stellate Cell Activation During Liver Fibrosis and Carcinogenesis
Barcena-Varela, M., Colyn, L., & Fernandez-Barrena, M. G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102507 · Cited by 72
Pham, T. X., Bae, M., Kim, M.-B., Lee, Y., Hu, S., Kang, H., Park, Y.-K., & Lee, J.-Y. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.06.009 · Cited by 73
Phenotypical and Functional Polymorphism of Liver Resident Macrophages
Elchaninov, A. V., Fatkhudinov, T., Vishnyakova, P., Lokhonina, А. V., & Sukhikh, G. T. (2019) · Cells · doi:10.3390/cells8091032 · Cited by 75
RETRACTED: The role of cardiac fibroblasts in post-myocardial heart tissue repair
Chistiakov, D. A., Orekhov, A. N., & Bobryshev, Y. V. (2016) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2016.09.002 · Cited by 75
RetractedLi, Y., Kang, X., Zhou, Z., Pan, L., Chen, H., Liang, X., Chu, J., Dong, S., Liu, C., Yu, S., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.07.020 · Cited by 73
Key Players of Hepatic Fibrosis
Dawood, R. M., El-Meguid, M. A., Salum, G. M., & Awady, M. K. E. (2020) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2020.0059 · Cited by 73
Hepatic Progenitor Cells in Action
Kaur, S., Siddiqui, H., & Bhat, M. H. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.06.004 · Cited by 72
Saif, M., Kwanten, W. J., Carr, J. A., Chen, I. X., Posada, J. M., Srivastava, A., Zhang, J., Zheng, Y., Pinter, M., Chatterjee, S., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0569-y · Cited by 70
Reversibility and heritability of liver fibrosis: Implications for research and therapy
Atta, H. M. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i17.5138 · Cited by 72
Arab, J. P., Cabrera, D., Sehrawat, T. S., Jalan‐Sakrikar, N., Verma, V. K., Simonetto, D. A., Cao, S., Yaqoob, U., León, J., Freire, M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.02.005 · Cited by 71
Self-citationRedente, E. F., Chakraborty, S., Sajuthi, S. P., Black, B. P., Edelman, B., Seibold, M. A., & Riches, D. W. H. (2020) · JCI Insight · doi:10.1172/jci.insight.141618 · Cited by 72
Potent natural products and herbal medicines for treating liver fibrosis
Chen, S.-R., Chen, X.-P., Lu, J.-J., Wang, Y., & Wang, Y.-T. (2015) · Chinese Medicine · doi:10.1186/s13020-015-0036-y · Cited by 64
Wilhelm, A., Shepherd, E. L., Amatucci, A., Munir, M., Reynolds, G., Humphreys, E., Resheq, Y., Adams, D. H., Hübscher, S., Burkly, L. C., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4707 · Cited by 67
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease
Schwabe, R. F., Tacke, F., Sugimoto, A., & Friedman, S. L. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101421 · Cited by 70
Siegmund, S., Schlosser, M., Schildberg, F. A., Seki, E., Minicis, S. D., Uchinami, H., Kuntzen, C., Knolle, P. A., Strassburg, C. P., & Schwabe, R. F. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150893 · Cited by 70
Roles of hepatic stellate cells in NAFLD: From the perspective of inflammation and fibrosis
Wang, M., Li, L., Xu, Y., Du, J., & Ling, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.958428 · Cited by 70
Mechanosignaling via Integrins: Pivotal Players in Liver Fibrosis Progression and Therapy
Sharip, A., & Kunz, J. (2025) · Cells · doi:10.3390/cells14040266 · Cited by 69
Potential effects of curcumin on peroxisome proliferator-activated receptor-γin vitroandin vivo
Mazidi, M., Karimi, E., Meydani, M., Ghayour‐Mobarhan, M., & Ferns, G. A. (2016) · World Journal of Methodology · doi:10.5662/wjm.v6.i1.112 · Cited by 69
Merkt, W., Zhou, Y., Han, H., & Lagares, D. (2021) · Wound Repair and Regeneration · doi:10.1111/wrr.12952 · Cited by 71
Myofibroblasts and inflammatory cells as players of cardiac fibrosis
Kurose, H., & Mangmool, S. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0809-6 · Cited by 68
Sphingosine-1-Phosphate Prevents Egress of Hematopoietic Stem Cells From Liver to Reduce Fibrosis
King, A., Houlihan, D. D., Kavanagh, D., Haldar, D., Luu, N., Owen, A., Suresh, S., Than, N. N., Reynolds, G., Penny, J., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.03.022 · Cited by 65
Hedgehog pathway and pediatric nonalcoholic fatty liver disease
Swiderska-Syn, M., Suzuki, A., Guy, C. D., Schwimmer, J. B., Abdelmalek, M. F., Lavine, J. E., & Diehl, A. M. (2013) · Hepatology · doi:10.1002/hep.26230 · Cited by 63
Human liver myofibroblasts during development and diseases with a focus on portal (myo)fibroblasts
Lepreux, S., & Desmoulière, A. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00173 · Cited by 58
Targeting Liver Fibrosis with a Cell-penetrating Protease-activated Receptor-2 (PAR2) Pepducin
Shearer, A. M., Rana, R., Austin, K. M., Baleja, J., Nguyen, N., Bohm, A., Covic, L., & Kuliopulos, A. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.732743 · Cited by 66
Chan, Y.-T., Wang, N., Tan, H. Y., Li, S., & Feng, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00548 · Cited by 66
Animal Models of Fibrosis in Nonalcoholic Steatohepatitis: Do They Reflect Human Disease?
Ipsen, D. H., Lykkesfeldt, J., & Tveden‐Nyborg, P. (2020) · Advances in Nutrition · doi:10.1093/advances/nmaa081 · Cited by 66
Engineering in vitro models of hepatofibrogenesis
Mazza, G., Al‐Akkad, W., & Rombouts, K. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.018 · Cited by 65
Fibrotic Events in the Progression of Cholestatic Liver Disease
Wu, H., Chen, C., Ziani, S., Nelson, L. J., Avila, M. A., Nevzorova, Y. A., & Cubero, F. J. (2021) · Cells · doi:10.3390/cells10051107 · Cited by 66
Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy
(2024) · doi:10.1146/annurev-pharmtox-020524-012013 · Cited by 64
Critical effects of long non-coding RNA on fibrosis diseases
Zhang, Y., Luo, G., Zhang, Y., Zhang, M., Zhou, J., Gao, W., Xuan, X., Yang, X., Yang, D., Tian, Z., et al. (2018) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.223 · Cited by 64
Human Induced Pluripotent Stem Cell-Derived Macrophages Ameliorate Liver Fibrosis
Pouyanfard, S., Meshgin, N., Cruz, L. S., Diggle, K., Hashemi, H., Pham, T. V., Fierro, M., Tamayo, P., Fanjul, A., Kisseleva, T., et al. (2021) · Stem Cells · doi:10.1002/stem.3449 · Cited by 59
Self-citationThe Origin and Fate of Liver Myofibroblasts
Kim, H. Y., Sakane, S., Eguileor, A., Carvalho Gontijo Weber, R., Lee, W., Liu, X., Lam, K., Ishizuka, K., Rosenthal, S. B., Diggle, K., et al. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.09.008 · Cited by 63
Self-citationPlatelet-derived Growth Factor Primes Cancer-associated Fibroblasts for Apoptosis
Ilyas, S. I., Mertens, J. C., Bronk, S. F., Hirsova, P., Dai, H., Roberts, L. R., Kaufmann, S. H., & Gores, G. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.563064 · Cited by 56
Vitamin A and insulin are required for the maintenance of hepatic stellate cell quiescence
Yoneda, A., Sakai, K., Niitsu, Y., & Tamura, Y. (2016) · Experimental Cell Research · doi:10.1016/j.yexcr.2016.01.012 · Cited by 63
da Silva, B. D. O., Ramos, L. F., & Moraes, K. C. M. (2017) · Cell Biology International · doi:10.1002/cbin.10790 · Cited by 64
Rom, O., Xu, G., Guo, Y., Zhu, Y., Wang, H. H., Zhang, J., Fan, Y., Liang, W., Lu, H., Liu, Y., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.019 · Cited by 63
Hepatic fibrosis: A convergent response to liver injury that is reversible
Wang, S., & Friedman, S. L. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.011 · Cited by 62
TWEAK-Fn14 Signaling Activates Myofibroblasts to Drive Progression of Fibrotic Kidney Disease
Gomez, I. G., Roach, A. M., Nakagawa, N., Amatucci, A., Johnson, B. G., Dunn, K., Kelly, M. C., Karaca, G., Zheng, T. S., Szak, S. T., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015111227 · Cited by 62
Okazaki, I., Noro, T., Tsutsui, N., Yamanouchi, E., Kuroda, H., Nakano, M., Yokomori, H., & Inagaki, Y. (2014) · Cancers · doi:10.3390/cancers6031220 · Cited by 61
Firouzi, D., Youssef, A., Amer, M., Srouji, R. M., Amleh, A., Foucher, D. A., & Bougherara, H. (2014) · Journal of the mechanical behavior of biomedical materials/Journal of mechanical behavior of biomedical materials · doi:10.1016/j.jmbbm.2014.01.001 · Cited by 61
Cipriani, P., Benedetto, P. D., Ruscitti, P., Campese, A. F., Liakouli, V., Carubbi, F., Pantano, I., Berardicurt, O., Screpanti, I., & Giacomelli, R. (2014) · Arthritis Research & Therapy · doi:10.1186/s13075-014-0442-z · Cited by 61
Antifibrotics in chronic liver disease: tractable targets and translational challenges
Ramachandran, P., & Henderson, N. C. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30110-8 · Cited by 50
Spontaneous Lung Fibrosis Resolution Reveals Novel Antifibrotic Regulators
Tan, Q., Link, P. A., Meridew, J. A., Pham, T. X., Caporarello, N., Ligresti, G., & Tschumperlin, D. J. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0396oc · Cited by 61
GATA4 induces liver fibrosis regression by deactivating hepatic stellate cells
Arroyo, N., Villamayor, L., Díaz, I., Carmona, R., Ramos-Rodríguez, M., Muñoz-Chápuli, R., Pasquali, L., Toscano, M. G., Martín, F., Cano, D. A., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.150059 · Cited by 60
“ed that, during the regression of liver fibrosis, approximately half of the aHSCs escape from apoptosis or cell senescence and revert their phenotype to an inactive or quiescent-like state, a process called deactivation (8).”
Davidson, M. D., Song, K. H., Lee, M., Llewellyn, J., Du, Y. M., Baker, B. M., Wells, R. G., & Burdick, J. A. (2019) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b01276 · Cited by 60
Hernández‐Aquino, E., Quezada‐Ramírez, M. A., Silva-Olivares, A., Casas‐Grajales, S., Ramos‐Tovar, E., Flores‐Beltrán, R. E., Segovia, J., Shibayama, M., & Muriel, P. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172730 · Cited by 60
Varma, S., Ambroise, J., Komuta, M., Latinne, D., Baldin, P., Reding, R., Smets, F., Stéphenne, X., & Sokal, E. M. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.05.040 · Cited by 59
Targeting collagen homeostasis for the treatment of liver fibrosis: Opportunities and challenges
Luangmonkong, T., Parichatikanond, W., & Olinga, P. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115740 · Cited by 58
Lua, I., James, D., Wang, J., Wang, K. S., & Asahina, K. (2014) · Hepatology · doi:10.1002/hep.27035 · Cited by 59
Reversibility of liver fibrosis.
Brenner, D. A. (2013) · Europe PMC (PubMed Central) · Cited by 58
Self-citationThe Space of Disse: The Liver Hub in Health and Disease
Sanz-García, C., Fernández-Iglesias, A., Gracia-Sancho, J., Arráez-Aybar, L. A., Nevzorova, Y. A., & Cubero, F. J. (2021) · Livers · doi:10.3390/livers1010002 · Cited by 57
“Nevertheless, cells stay in a stage that predisposes them to reactivate into myofibroblast, after a local stimulus, developing a more severe stage of fibrosis [144]; thus, full recovery cannot be achieved and more studies have to be developed to address this issue.”
BackgroundMelhem, M. R., Park, J., Knapp, L., Reinkensmeyer, L., Cvetkovic, C., Flewellyn, J., Lee, M. K., Jensen, T. W., Bashir, R., Kong, H., et al. (2017) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.6b00176 · Cited by 55
Lu, D., Aroonsakool, N., Yokoyama, U., Patel, H. H., & Insel, P. A. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.087742 · Cited by 56
Activation of pericytes: recent insights into kidney fibrosis and microvascular rarefaction
Fligny, C., & Duffield, J. S. (2012) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32835b656b · Cited by 57
Morin enhances hepatic Nrf2 expression in a liver fibrosis rat model
Sang, L., Wang, X., Xu, D.-Y., Sang, L.-X., Han, Y., & Jiang, L. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i47.8334 · Cited by 56
Animal models for hepatocellular carcinoma
Zhang, H. E., Henderson, J. M., & Gorrell, M. D. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.08.009 · Cited by 57
Fibrogenic cell reversion underlies fibrosis regression in liver
Friedman, S. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206645109 · Cited by 48
Crespo, I., San‐Miguel, B., Fernández, A. M. C., de Urbina, J. J. O., González‐Gallego, J., & Tuñón, M. J. (2014) · Translational research · doi:10.1016/j.trsl.2014.10.003 · Cited by 55
Fareed, M. M., Khalid, H., Khalid, S., & Shityakov, S. (2023) · Current Molecular Medicine · doi:10.2174/0115665240257603230919103539 · Cited by 54
Astaxanthin prevents and reverses the activation of mouse primary hepatic stellate cells
Yang, Y. J., Bae, M., Kim, B., Park, Y., Koo, S. I., & Lee, J. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.11.005 · Cited by 54
Xia, S., Liu, Z., Cai, J., Ren, H., Li, Q., Zhang, H., Jing, Y., Zhou, Q., Zhou, T., Wang, L., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.052 · Cited by 53
Unraveling the molecular architecture of autoimmune thyroid diseases at spatial resolution
Martínez‐Hernández, R., de la Blanca, N. S., Sacristan-Gomez, P., Serrano-Somavilla, A., de Nova, J. L. M., Sánchez‐Cabo, F., Heyn, H., Sampedro-Nuñez, M. A., & Marazuela, M. (2024) · Nature Communications · doi:10.1038/s41467-024-50192-5 · Cited by 53
Mannaerts, I., Schroyen, B., Verhulst, S., Lommel, L. V., Schuit, F. C., Nyssen, M., & van Grunsven, L. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084071 · Cited by 53
Athwal, V. S., Pritchett, J. P., Llewellyn, J., Martin, K., Camacho, E. M., Raza, S., Phythian‐Adams, A., Birchall, L., Mullan, A. F., Su, K., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707860 · Cited by 53
LncRNA GAS5-AS1 inhibits myofibroblasts activities in oral submucous fibrosis
Lin, C.-Y., Liao, Y., Hsieh, P., Lu, M., Peng, C., Chu, P., Yang, H., Huang, Y., Yu, C., & Yu, C. (2017) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2017.09.012 · Cited by 53
Hedgehog Signaling Demarcates a Niche of Fibrogenic Peribiliary Mesenchymal Cells
Gupta, V., Gupta, I., Park, J., Bram, Y., & Schwartz, R. E. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.03.075 · Cited by 53
Gart, E., van Duyvenvoorde, W., Toet, K. H., Caspers, M. P. M., Verschuren, L., Nielsen, M. J., Leeming, D. J., Lima, E. S., Menke, A. L., Hanemaaijer, R., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9121954 · Cited by 54
Entrapment of the suprascapular nerve: anatomy, etiology, diagnosis, treatment.
Gosk, J., Urban, M., & Rutowski, R. (2007) · PubMed · Cited by 53
Metadata
- Authors
- Kisseleva, T., Cong, M., Paik, Y., Scholten, D., Jiang, C., Benner, C., Iwaisako, K., Moore-Morris, T., Scott, B., Tsukamoto, H., Evans, S. M., Dillmann, W., Glass, C. K., & Brenner, D. A.
- Affiliations
- Department of Medicine,
- Universitätsklinikum Aachen (DE)
- Department of Cellular and Molecular Medicine,
- School of Pharmacy, University of California, San Diego, CA 92093;
- University of Southern California (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2012-05-07
- Volume
- 109
- Issue
- 24
- Pages
- 9448-9453
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3386114
- OpenAlex
- W2075290880
- Cited by
- 805
- References
- 27
- Citations by year
- 2026: 29 · 2025: 51 · 2024: 61 · 2023: 59 · 2022: 53 · 2021: 62 · 2020: 64 · 2019: 52 · 2018: 53 · 2017: 61 · 2016: 64 · 2015: 73 · 2014: 63 · 2013: 42 · 2012: 13
- FWCI
- 38.69
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM041804)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- myofibroblasts, hepatic stellate cells, liver fibrosis, fibrosis regression, apoptosis, anti-apoptotic genes, carbon tetrachloride, alcohol-induced liver injury, fibrogenic gene expression
- MeSH terms
- Animals, Liver Cirrhosis, Phenotype, Tamoxifen, Adoptive Transfer, Collagen Type I, Mice, Myofibroblasts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.